ジンセノサイドRg3
Based on 9 publication(s) in Google Scholar
20(S)-Ginsenoside Rg3 is the main component of Panax ginseng C. A. Meyer. Ginsenoside Rg3 inhibits Na+ and hKv1.4 channel with IC50s of 32.2±4.5 and 32.6±2.2 μM, respectively. 20(S)-Ginsenoside Rg3 also inhibits Aβ levels, NF-κB activity, and COX-2 expression.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.82%
- CAS 番号: 14197-60-5
- 分子式: C42H72O13
- 分子量:785.01
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-N0039
Ginsenoside Rb1
-
HY-N0605
Ginsenoside Rh2
-
HY-N0045
Ginsenoside Rg1
-
HY-N0904
Ginsenoside C-K
-
HY-15097
Myricetin
-
HY-N0604
Ginsenoside Rh1
-
HY-N1376
(20R)-Ginsenoside Rg3
-
HY-N0752
Scutellarein
-
HY-N2515
Ginsenoside Rk1
-
HY-N0058
4,5-Dicaffeoylquinic acid
-
HY-N0176
Dihydroartemisinin
-
HY-18085
Quercetin
MedChemExpress（MCE）の使用を引用している文献 20(S)-Ginsenoside Rg3
More- Pharmacol Res. 2020 May:155:104751. [Abstract]
- Phytomedicine. 2026 Jul:156:158272. [Abstract]
- Phytomedicine. 2026 Feb:151:157792. [Abstract]
- Food Res Int. 2022 Jun:156:111155. [Abstract]
- Int J Mol Med. 2022 Jul;50(1):89. [Abstract]
- Int Immunopharmacol. 2021 Sep:98:107841. [Abstract]
- Immun Inflamm Dis. 2026 Feb;14(2):e70362. [Abstract]
- J Fluoresc. 2025 Sep 27. [Abstract]
- Cytotechnology. 2026 Jun;78(3):79. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Cell Migration/Invasion Assay
-
In Vivo Efficacy Study
-
WB
Endogenous Metabolite アイソフォーム固有の製品をすべて表示
More
生物活性
|
Na+ channel 32.2 μM (IC50) |
hKv1.4 channel 32.6 μM (IC50) |
p65 |
COX-2 |
Aβ40 |
Aβ42 |
Ginsenoside Rg3 plays an important role in its effect on the Na+ channel. Treatment with Ginsenoside Rg3 reversibly inhibits the inward Na+ peak current (INa) with an IC50 of 32.2±4.5 μM, and the inhibition is voltage-dependent[1]. Ginsenoside Rg3 at 100 μM inhibits the hKv1.4 channel currents by an average of 65%.The Ginsenoside Rg3 effect is concentration-dependent and reversible. The IC50 value and Hill coefficient are 32.6±2.2 μM and 1.59±0.13, respectively[2]. Ginsenoside Rg3 shows the significant inhibition of NF-κB activity thereby reduced COX-2 expression. To examine the cytotoxicity of Ginsenoside Rg3 on IL-1β-induced inflamed A549 cells, the cells are firstly treated with IL-1β (10 ng/mL) for 4 h and treated with 100 to 900 ng/mL concentration of Ginsenoside Rg3 for 12 h. Cell viability is analyzed using an MTT assay. There is no observed cytotoxicity of Ginsenoside Rg3 in IL-1β-induced inflamed A549 cells compared to only PBS-treated cells (Con).To obtain the anti-inflammatory effects of Ginsenoside Rg3 on inflammation induced human lung epithelial cells, A549 cells inflammation is induced by IL-1β (10 ng/mL) and then treated by 5 μM of Dexamethasone (Dex) or 900 nM of Rg3. The NF-κB activation is analyzed by a western blot analysis to evaluate the effect of Ginsenoside Rg3 treatment on A549 cells. Phospho-NF-κB p65/total NF-κB p65 densitometry in the cells treated with Rg3 shows the significant decrease compared to IL-1β-induced inflamed A549 cells. The meaning of reducing the ratio of p-p65/p65 by Rg3 treatment is associated with NF-κB activation. Ginsenoside Rg3 also downregulates the expression of COX-2 effectively[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 14197-60-5
-
性状 Solid
-
分子量 785.01
-
分子式 C42H72O13
-
Color White to off-white
-
SMILES
O[C@@H]([C@@H]([C@@H](CO)O1)O)[C@@H](O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)[C@@H]1O[C@H]3CC[C@]4(C)[C@@]5([H])C[C@@H](O)[C@]6([H])[C@@H](C(C)(O)CC/C=C(C)\C)CC[C@](C)6[C@@](C)5CCC4C3(C)C
-
別名
20(S)-Ginsenoside Rg3; 20(S)-Propanaxadiol; S-ginsenoside Rg3
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Pharmacol Res
Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. [Abstract]2020 May:155:104751. PMID: 32151678 -
Phytomedicine
Ginsenoside Rg3 improves atezolizumab immune checkpoint therapy in triple-negative breast cancer by targeting FUT8-mediated PD-L1 N-glycosylation. [Abstract]2026 Jul:156:158272. PMID: 42102789 -
Phytomedicine
Ginsenoside Rg3 antagonises endometriosis glycolysis via the tripartite motif containing 28 and pyruvate dehydrogenase kinase 4 signalling pathway. [Abstract]2026 Feb:151:157792. PMID: 41539092
20(S)-Ginsenoside Rg3 purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Feb:151:157792. [Abstract]
IC₅₀ values of ESCs after treatment with 20(S)-Ginsenoside Rg3 (Rg3).
20(S)-Ginsenoside Rg3 purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Feb:151:157792. [Abstract]
ESC activity after treatment with 20(S)-Ginsenoside Rg3 (Rg3) or dinogest.
20(S)-Ginsenoside Rg3 purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Feb:151:157792. [Abstract]
Transwell migration following treatment with 20(S)-Ginsenoside Rg3 (Rg3) or dinogest.
20(S)-Ginsenoside Rg3 purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Feb:151:157792. [Abstract]
Representative images of ectopic endometrial lesions in mice were obtained from the blank control group, the dinogest group, and two different doses of 20(S)-Ginsenoside Rg3 (Rg3) groups.
20(S)-Ginsenoside Rg3 purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Feb:151:157792. [Abstract]
Expression of PDK4 protein in ESCs and 11Z cells after treatment with 20(S)-Ginsenoside Rg3 (Rg3: 17.21 μM).
-
Food Res Int
Transformation of ginsenosides by moderate heat-moisture treatment and their cytotoxicity toward HepG2 cells. [Abstract]2022 Jun:156:111155. PMID: 35651021 -
Int J Mol Med
Ginsenoside Rg3 ameliorates acute pancreatitis by activating the NRF2/HO‑1‑mediated ferroptosis pathway. [Abstract]2022 Jul;50(1):89. PMID: 35582998 -
Int Immunopharmacol
Ginsenoside Rg3 attenuates angiotensin II-induced myocardial hypertrophy through repressing NLRP3 inflammasome and oxidative stress via modulating SIRT1/NF-κB pathway. [Abstract]2021 Sep:98:107841. PMID: 34153662 -
Immun Inflamm Dis
Ginsenoside Rg3 Ameliorates Psoriasis-Like Dermatitis through Inhibition of NF-κB/NLRP3 Inflammasome Signaling and Regulating Th17/Treg Balance. [Abstract]2026 Feb;14(2):e70362. PMID: 41699408 -
J Fluoresc
Microbial-Modified Organosilica-Based Dual-Mode Fluorescent Probe for Zn²⁺ and pH Sensing with Potential Application in Gut Immunity Modulation. [Abstract]2025 Sep 27. PMID: 41014421 -
Cytotechnology
20(S)-Ginsenoside Rg3 suppresses lung cancer-associated fibroblast activation associated with IL-17RD-FGF-MAP2K4-JNK signaling. [Abstract]2026 Jun;78(3):79. PMID: 41953106
溶剤 & 溶解度
DMSO : 100 mg/mL (127.39 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
プロトコル
MTT assays are performed to evaluate the cytotoxicity of Ginsenoside Rg3 on inflamed cells. Ten thousands of A549 cells cultured each well of 96-well plate and are incubated at 37°C and 5% CO2 overnight. After serum starvation using DMEM low glucose without FBS, the medium is changed into RPMI containing IL-1β (10 ng/mL) and the cells are incubated at 37°C and 5% CO2 for 4 h. After 4 h incubation, the cells are treated with Ginsenoside Rg3 (100-900 nM) for 12 h. Thirty microliters of MTT solution (5 mg/mL) is added to each well and the cells are incubated for 2 h. After 2 h incubation in cell culture incubator, the medium containing MTT solution of each well is removed and 50 μL of DMSO is added. Using an automated spectrophotometric plate reader at 570 nm, the optical density of formazan is measured[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[4]
The mice used are heterozygous, double transgenic animals expressing both human APP(K670N/M671L) and PS1(M146L) proteins. These Alzheimer disease model mice are age-matched (3 months old) in all experiments with wild-type littermates. Both sets of mice are produced by crossing heterozygous APP mice with heterozygous PS1 mice and are weaned at 3 weeks and genotyped by PCR of digested tail samples. Ginsenoside Rg3 is prepared in a saline solution containing 0.01% DMSO at a concentration of 10 mg/kg of body weight. Ginsenoside Rg3 (or saline with 0.01% DMSO for controls) is administered daily via intraperitoneal injection. After sacrifice, one hemibrain from each mouse is frozen on dry ice, homogenized in sucrose buffer, and extracted via formic acid for Aβ quantification using a commercial sandwich ELISA kit.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
純度とドキュメンテーション
-
データシート (285 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Kim JH, et al. A role for the carbohydrate portion of ginsenoside Rg3 in Na+ channel inhibition. Mol Cells. 2005 Feb 28;19(1):137-42. [Content Brief]
[2]. Lee JH, et al. Ginsenoside Rg3 inhibits human Kv1.4 channel currents by interacting with the Lys531 residue. Mol Pharmacol. 2008 Mar;73(3):619-26. [Content Brief]
[3]. Lee IS, et al. Anti-Inflammatory Effects of Ginsenoside Rg3 via NF-κB Pathway in A549 Cells and Human Asthmatic Lung Tissue. J Immunol Res. 2016;2016:7521601. [Content Brief]
[4]. Kang MS, et al. Modulation of lipid kinase PI4KIIα activity and lipid raft association of presenilin 1 underlies γ-secretase inhibition by ginsenoside (20S)-Rg3. J Biol Chem. 2013 Jul 19;288(29):20868-82. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2739 mL | 6.3693 mL | 12.7387 mL | 31.8467 mL |
| 5 mM | 0.2548 mL | 1.2739 mL | 2.5477 mL | 6.3693 mL | |
| 10 mM | 0.1274 mL | 0.6369 mL | 1.2739 mL | 3.1847 mL | |
| 15 mM | 0.0849 mL | 0.4246 mL | 0.8492 mL | 2.1231 mL | |
| 20 mM | 0.0637 mL | 0.3185 mL | 0.6369 mL | 1.5923 mL | |
| 25 mM | 0.0510 mL | 0.2548 mL | 0.5095 mL | 1.2739 mL | |
| 30 mM | 0.0425 mL | 0.2123 mL | 0.4246 mL | 1.0616 mL | |
| 40 mM | 0.0318 mL | 0.1592 mL | 0.3185 mL | 0.7962 mL | |
| 50 mM | 0.0255 mL | 0.1274 mL | 0.2548 mL | 0.6369 mL | |
| 60 mM | 0.0212 mL | 0.1062 mL | 0.2123 mL | 0.5308 mL | |
| 80 mM | 0.0159 mL | 0.0796 mL | 0.1592 mL | 0.3981 mL | |
| 100 mM | 0.0127 mL | 0.0637 mL | 0.1274 mL | 0.3185 mL |
20(S)-Ginsenoside Rg3 関連分類
HY-N0603 関連分類
Powered by Bioz